Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Rangering i aksjer #2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aksjekurs
$114.06
Sist synkronisert: 2026-10-20
Markedsverdi
$9.38B
Endring (1 dag)
5.54%
Endring (1 år)
95.57%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)

Kategori

Healthcare
P/S-forhold for Kymera Therapeutics, Inc. (KYMR)
P/S-forhold per October 2026 TTM: 83.70
Ifølge Kymera Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 83.70. Ved slutten av 2023 hadde selskapet et P/S-forhold på 18.91.
P/S-historikk for Kymera Therapeutics, Inc. fra 2018 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 83.70 30.50%
2024 64.14 239.21%
2023 18.91 -34.23%
2022 28.75 -31.28%
2021 41.83 -48.46%
2020 81.17 -83.92%
2019 504.79 0.00%
2018 0.00 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.02 -88.03%
US
40.55 -51.55%
US
3.96 -95.27%
AU
- -
CH
10.15 -87.88%
NL